In early preclinical studies with animal models, the novel procedure significantly inhibited tumor growth. Focusing on the neurotensin receptor 1 (NTR1), a protein that is overexpressed in ductal pancreatic adenocarcinoma, researchers developed a DOTA-conjugated NTR1 antagonist 3BP-227 labeled with the radioisotope lutetium-177 (177Lu) to treat and monitor therapy. For this study, 6 patients with confirmed metastatic ductal pancreatic adenocarcinoma, who had exhausted all other treatment options, received 177Lu-3BP-227 as salvage therapy. Scintigraphy and single-photon emission computed tomography was used with computed tomography (SPECT/CT) to determine the tumor uptake and the patients’ eligibility for treatment. If the patient’s condition allowed, 18F-FDG positron emission tomography (PET)/CT imaging was performed 8-12 weeks after therapy to determine treatment efficacy.
Read more at http://bit.ly/2wxjRzn
Submit manuscript at firstname.lastname@example.org